BioCentury | Mar 30, 2021
Finance

With ADC pipeline now a top priority, Pyxis adds $152M series B

...2019 based on insights into tumor biology by co-founder Thomas Gajewski, a professor at the University of Chicago...
BioCentury | Mar 27, 2021
Translation in Brief

Lentigen’s trispecific CAR Ts; plus a bispecific antiviral COVID-19 mAb, Wild Biotech, Kancera and more

...in Biomedicine Academy of Sciences of the Czech Republic University of Chicago Miltenyi...
BioCentury | Mar 18, 2021
Deals

Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech

...Bayer, Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY) and angel investors. It was spun out of the University of Chicago...
BioCentury | Dec 10, 2020
Management Tracks

Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

...the division of ophthalmology for NorthShore University HealthSystem and is a clinical professor of ophthalmology at University of Chicago...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Targeting an mRNA epigenetic reader protein for breast cancer brain metastasis

...Oct. 29, 2020doi:10.1016/j.ccell.2020.10.004CONTACT: Chuan He, University of Chicago, Chicago, Ill.email: chuanhe@uchicago.eduCONTACT: Suyun Huang, Virginia Commonwealth University School of Medicine, Richmond, Va.email: suyun.huang@vcuhealth.org Claire Quang University of Chicago Virginia...
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...Inc., Navigen Pharmaceuticals Inc. and Recursion Pharmaceuticals Inc. A University of Chicago...
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

...Danielle Golovin, Staff Writer  Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago...
...NFKB1; p105; p50) – Nuclear factor of κ light polypeptide gene enhancer in B cells 1 BC Staff University of Chicago City...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

...of placebo (both used SOC as the comparator), but they suggest follow-up studies are warranted. University of Chicago...
BioCentury | Apr 23, 2020
Product Development

First glimpse of controlled remdesivir data cast doubt on its COVID-19 treatment potential

...that added $9.4 billion to the biotech’s market cap. Comments from an investigator at the University of Chicago...
BioCentury | Apr 17, 2020
Finance

Next inflection points come into focus for Gilead, Moderna following Friday’s big gains

...amounting to a $9.4 billion market cap gain Friday. Comments from an investigator at the University of Chicago...
Items per page:
1 - 10 of 302
BioCentury | Mar 30, 2021
Finance

With ADC pipeline now a top priority, Pyxis adds $152M series B

...2019 based on insights into tumor biology by co-founder Thomas Gajewski, a professor at the University of Chicago...
BioCentury | Mar 27, 2021
Translation in Brief

Lentigen’s trispecific CAR Ts; plus a bispecific antiviral COVID-19 mAb, Wild Biotech, Kancera and more

...in Biomedicine Academy of Sciences of the Czech Republic University of Chicago Miltenyi...
BioCentury | Mar 18, 2021
Deals

Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech

...Bayer, Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY) and angel investors. It was spun out of the University of Chicago...
BioCentury | Dec 10, 2020
Management Tracks

Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

...the division of ophthalmology for NorthShore University HealthSystem and is a clinical professor of ophthalmology at University of Chicago...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Targeting an mRNA epigenetic reader protein for breast cancer brain metastasis

...Oct. 29, 2020doi:10.1016/j.ccell.2020.10.004CONTACT: Chuan He, University of Chicago, Chicago, Ill.email: chuanhe@uchicago.eduCONTACT: Suyun Huang, Virginia Commonwealth University School of Medicine, Richmond, Va.email: suyun.huang@vcuhealth.org Claire Quang University of Chicago Virginia...
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...Inc., Navigen Pharmaceuticals Inc. and Recursion Pharmaceuticals Inc. A University of Chicago...
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

...Danielle Golovin, Staff Writer  Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago...
...NFKB1; p105; p50) – Nuclear factor of κ light polypeptide gene enhancer in B cells 1 BC Staff University of Chicago City...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

...of placebo (both used SOC as the comparator), but they suggest follow-up studies are warranted. University of Chicago...
BioCentury | Apr 23, 2020
Product Development

First glimpse of controlled remdesivir data cast doubt on its COVID-19 treatment potential

...that added $9.4 billion to the biotech’s market cap. Comments from an investigator at the University of Chicago...
BioCentury | Apr 17, 2020
Finance

Next inflection points come into focus for Gilead, Moderna following Friday’s big gains

...amounting to a $9.4 billion market cap gain Friday. Comments from an investigator at the University of Chicago...
Items per page:
1 - 10 of 302